Morgan Stanley Decibel Therapeutics, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.41 - $4.81 $22,957 - $45,820	-9,526 Reduced 59.07%	6,600 $25,000
Q1 2023 May 15, 2023	BUY	$2.08 - $4.79 $11,577 - $26,661	5,566 Added 52.71%	16,126 $48,000
Q4 2022 Feb 14, 2023	SELL	$1.86 - $3.54 $2,812 - $5,352	-1,512 Reduced 12.52%	10,560 $21,000
Q3 2022 Nov 14, 2022	BUY	$3.82 - $5.61 $3,984 - $5,851	1,043 Added 9.46%	12,072 $42,000
Q2 2022 Oct 27, 2022	SELL	$1.85 - $4.21 $21,852 - $49,728	-11,812 Reduced 51.71%	11,029 $46,000
Q2 2022 Aug 15, 2022	SELL	$1.85 - $4.21 $21,852 - $49,728	-11,812 Reduced 51.71%	11,029 $46,000
Q1 2022 Oct 27, 2022	BUY	$2.83 - $5.03 $33,427 - $59,414	11,812 Added 107.1%	22,841 $69,000
Q1 2022 May 13, 2022	BUY	$2.83 - $5.03 $27,108 - $48,182	9,579 Added 72.23%	22,841 $69,000
Q4 2021 Feb 14, 2022	SELL	$4.57 - $8.58 $68,056 - $127,773	-14,892 Reduced 52.89%	13,262 $62,000
Q3 2021 Nov 15, 2021	BUY	$6.6 - $9.04 $185,816 - $254,512	28,154 New	28,154 $217,000

Ticker DBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,964,500
Description
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.